Webinar: Exploring Current Payer Price Sensitivities
Understanding the relationship between pharmaceutical manufacturers and payers in 2022
In this webinar recording, Amplity's Cheryl Nagowski and Dan Cusack walk participants through the current thinking around payer price sensitivities. This session explores why manufacturers are beginning to roll the dice with their pre-commercial assets and step away from the payer table.
Watch now for our take on this new market access paradigm as you prepare your commercialization strategy for 2022 and beyondBy watching this webinar, you will learn:
- Payer negotiation opening stance
- What’s happening with the 6mo PBM NDC block upon launch
- Why it’s about the rebate and not the price
Ready to talk Market Access strategy?Click here to set up a meeting with the speakers of this webinar, Cheryl and Dan.
Meet the Author
As Head of Market Access, Cheryl develops and enhances managed care strategies for our pharmaceutical, biopharmaceutical, and medical device clients. She uses data-driven insights to inform pricing, contracting, and strategic recommendations at all product life cycle stages. She has been called to improve patient access to cutting-edge innovations, including gene therapy and crucial advances in rare diseases. Before joining Team Amplity, Cheryl founded a consulting firm devoted to helping life science companies maximize the coverage and adoption of their products. An expert in Federal market optimization, Cheryl has worked extensively to assist clients in launching and growing their market share in this challenging segment. Cheryl started her career in the pharma industry at Genentech where she managed national, regional, and federal payer pricing, contracting, and strategy. Before entering the pharmaceutical arena, she worked as a buyer and negotiator for the Department of Defense in research programs. Cheryl holds an MPS in Strategic Public Relations from George Washington University.